Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects
Combining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/5/429 |
id |
doaj-18eb9c6605c542879e708530f4c1ebda |
---|---|
record_format |
Article |
spelling |
doaj-18eb9c6605c542879e708530f4c1ebda2021-05-31T23:06:13ZengMDPI AGPharmaceuticals1424-82472021-05-011442942910.3390/ph14050429Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction EffectsPieter Dewulf0Michiel Stock1Bernard De Baets2KERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumKERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumKERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, Coupure Links 653, 9000 Gent, BelgiumCombining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number of combinations to predict for all. In this work, we identify various subtasks in predicting effects caused by drug–drug interaction. Predicting drug–drug interaction effects for drugs that already exist is very different from predicting outcomes for newly developed drugs, commonly called a cold-start problem. We propose suitable validation schemes for the different subtasks that emerge. These validation schemes are critical to correctly assess the performance. We develop a new model that obtains AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.843</mn></mrow></semantics></math></inline-formula> for the hardest cold-start task up to AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.957</mn></mrow></semantics></math></inline-formula> for the easiest one on the benchmark dataset of Zitnik et al. Finally, we illustrate how our predictions can be used to improve post-market surveillance systems or detect drug–drug interaction effects earlier during drug development.https://www.mdpi.com/1424-8247/14/5/429polypharmacydrug–drug interactionpredictioncross-validationmachine learningcold-start problems |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pieter Dewulf Michiel Stock Bernard De Baets |
spellingShingle |
Pieter Dewulf Michiel Stock Bernard De Baets Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects Pharmaceuticals polypharmacy drug–drug interaction prediction cross-validation machine learning cold-start problems |
author_facet |
Pieter Dewulf Michiel Stock Bernard De Baets |
author_sort |
Pieter Dewulf |
title |
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects |
title_short |
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects |
title_full |
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects |
title_fullStr |
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects |
title_full_unstemmed |
Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects |
title_sort |
cold-start problems in data-driven prediction of drug–drug interaction effects |
publisher |
MDPI AG |
series |
Pharmaceuticals |
issn |
1424-8247 |
publishDate |
2021-05-01 |
description |
Combining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number of combinations to predict for all. In this work, we identify various subtasks in predicting effects caused by drug–drug interaction. Predicting drug–drug interaction effects for drugs that already exist is very different from predicting outcomes for newly developed drugs, commonly called a cold-start problem. We propose suitable validation schemes for the different subtasks that emerge. These validation schemes are critical to correctly assess the performance. We develop a new model that obtains AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.843</mn></mrow></semantics></math></inline-formula> for the hardest cold-start task up to AUC-ROC <inline-formula><math xmlns="http://www.w3.org/1998/Math/MathML" display="inline"><semantics><mrow><mo>=</mo><mn>0.957</mn></mrow></semantics></math></inline-formula> for the easiest one on the benchmark dataset of Zitnik et al. Finally, we illustrate how our predictions can be used to improve post-market surveillance systems or detect drug–drug interaction effects earlier during drug development. |
topic |
polypharmacy drug–drug interaction prediction cross-validation machine learning cold-start problems |
url |
https://www.mdpi.com/1424-8247/14/5/429 |
work_keys_str_mv |
AT pieterdewulf coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects AT michielstock coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects AT bernarddebaets coldstartproblemsindatadrivenpredictionofdrugdruginteractioneffects |
_version_ |
1721418258648662016 |